US regulatory status: approved.
pharma · Duchenne Muscular Dystrophy · Muscular Dystrophy, Duchenne · SRPT
Sarepta Therapeutics
Sarepta Therapeutics drug portfolio — 23 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
215 First Street, Cambridge, MA 02142, US HQ
1,150 Employees
Public company Type
SRPT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 215 First Street, Cambridge, MA 02142, US
- Employees
- 1,150
- Programs
- 46
- Drugs
- 23
- Patents
- 102
Sarepta Therapeutics pipeline
Portfolio lens on 23 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Sarepta Therapeutics drug portfolio — 23 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
- Target
- DNA polymerase catalytic subunit
- Mechanism
- Human herpesvirus 1 DNA polymerase inhibitor
-
US regulatory status: approved. Molecular target: Dystrophin pre-mRNA.
- Target
- Dystrophin pre-mRNA
- Mechanism
- Dystrophin pre-mRNA positive modulator
-
Development asset linked to Sarepta Therapeutics in public FDA and regional records.
-
delandistrogene moxeparvovec
Musculo-skeletal system (M09)Musculo-skeletal system (M09) compound in Sarepta Therapeutics's portfolio. Molecular target: Dystrophin.
- Target
- Dystrophin
- Mechanism
- Dystrophin exogenous gene
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
eteplirsen
Musculo-skeletal system (M09)US regulatory status: approved. Molecular target: Dystrophin pre-mRNA.
- Target
- Dystrophin pre-mRNA
- Mechanism
- Dystrophin pre-mRNA positive modulator
-
US regulatory status: approved. Molecular target: Dystrophin pre-mRNA.
- Target
- Dystrophin pre-mRNA
- Mechanism
- Dystrophin pre-mRNA positive modulator
-
imlifidase
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in Sarepta Therapeutics's portfolio. Molecular target: Antibodies.
- Target
- Antibodies
- Mechanism
- Antibodies hydrolytic enzyme
-
influenza vaccine (h1n1)v (split virion, inactivated, adjuvanted)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Sarepta Therapeutics's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
influenza vaccine (live attenuated, nasal)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Sarepta Therapeutics's portfolio.
-
Development asset linked to Sarepta Therapeutics in public FDA and regional records.
-
Development asset linked to Sarepta Therapeutics in public FDA and regional records.
-
Development asset linked to Sarepta Therapeutics in public FDA and regional records.
-
japanese encephalitis vaccine (inactivated, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Sarepta Therapeutics's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
Development asset linked to Sarepta Therapeutics in public FDA and regional records.
-
Development asset linked to Sarepta Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Sarepta Therapeutics in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Sarepta Therapeutics in public FDA and regional records.
-
Development asset linked to Sarepta Therapeutics in public FDA and regional records.
-
Development asset linked to Sarepta Therapeutics in public FDA and regional records.